More

    New Peer Review Proves COVAXIN Booster Dose Provides Multiple Benefits

    According to a new peer-reviewed study, administration of Bharat Biotech’s COVAXIN Booster (3rd dose), after 6 months of two dose vaccination, dramatically increased neutralizing antibody responses against both homologous and heterologous strains (Alpha, Beta, Delta, Delta Plus and Omicron) and showed increased memory B cell response.

    According to the latest peer review study published in Nature, COVAXIN, its whole-virion inactivated COVID-19 vaccine, has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials.

    This is a comprehensive study that has demonstrated multiple benefits of COVAXIN, such as long term immune response, cell mediated immunity, safety of booster dose, immunogenicity against spike protein, N protein and neutralizing antibody responses against alpha, beta, delta, delta plus and omicron variants.

    The study has been accepted and published in Nature Scientific Reports, a high impact factor journal.

    Highlights COVAXIN Booster Dose Study

    This COVAXIN data is now peer reviewed and published in Nature Scientific Reports, a high impact factor journal.

    • Administration of a third dose, after 6 months of two dose vaccination, dramatically increased neutralizing antibody responses against both homologous and heterologous strains (Alpha, Beta, Delta, Delta Plus and Omicron) and showed increased memory B cell response.
    • COVAXIN induced robust T cell responses and persisted till 6 months, even after antibody decline. These T cell responses have been followed up to 12 months in vaccinated individuals, irrespective of receipt of third dose. T cell responses in turn help to produce B cell memory response, upon antigen re-exposure. Thus, COVAXIN provides long term immunity.
    • Immune responses declined at 6 months, but increased by 40 fold in subjects who received a booster dose. Immune responses when assessed against variants of concern and persisted up to 12 months.
    • No serious adverse events observed, except pain at the injection site, itching and redness, no cases of myocarditis, pericarditis, blood clots, or thrombocytopenia were detected.
    • The study provides evidence to support COVAXIN, a multi epitope vaccine that provides broad protection against variants couples with cell mediated immune response due to the use of novel adjuvant Algel-IMDG.

    Peer Reviewed: COVAXIN demonstrates Persistence of immunity and impact of third dose of inactivated COVID‐19 vaccine against emerging variants – Bharat Biotech

    The study was conducted in ~184 subjects, who were randomized 1:1 and received either a booster dose of BBV152 or a placebo, ~6 months after the primary series of 2 doses. Subjects were evaluated for safety, neutralizing antibody responses against variants of concern, binding antibodies against spike protein, RBD, N proteins, and for memory T and B cell responses to demonstrate cell mediated immunity.

    Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Our team has now demonstrated that COVAXIN is a multi epitope vaccine with antibodies against spike, RBD and N proteins. Post booster dose, it has proven neutralizing antibody responses against variants of concern and long term protection through memory T and B cell responses. We have now achieved our goal of developing a safe and efficacious vaccine with long term protection against a spectrum of variants.”

    COVAXIN, is formulated uniquely such that the same dosage can be administered to adults and children alike, for primary and booster doses, making it truly a universal vaccine. COVAXIN is a ready to use liquid vaccine, stored at 2-8 degree C, with 12 months shelf life and multi dose vial policy.

    Whole virion inactivated vaccines have proven to be safe, tolerable with a safety track record of several decades. Several paediatric vaccines manufactured using this platform technology are utilized in routine immunization for primary immunization and booster doses. Several flu vaccines also utilize this manufacturing platform technology, which is safe and effective for repeated annual immunization doses and boosters.

    Bharat Biotech has a stockpile of more than 50 million doses of COVAXIN ready to be distributed as required.

    Share

    Latest Updates

    Related Articles

    Vizag Tech Summit 2023 announces INR 3000 Cr Projected Investments

    The Vizag Tech Summit 2023 will be held on February 16th and 17th, 2023...

    iNCOVACC Fast Facts: World’s first Intranasal vaccine approved by India

    Bharat Biotech iNCOVACC®️ (BBV154), has received approval from the Central Drugs Standard Control Organisation...

    China’s Foxconn’s factory unrest may lead to serious shortage of iPhone’s

    Foxconn's factory in Zhengzhou, China, is experiencing employee unrest that could lead to a...

    Fear of T20 taking away the best players plagues international cricket

    T20 Cricket is threating national teams globally as players seem to prefer playing T20...